These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles. Rajaram L; Roy SK; Skerjanec A Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918 [TBL] [Abstract][Full Text] [Related]
26. Extension to the use of tolerance intervals for the assessment of individual bioequivalence. Esinhart JD; Chinchilli VM J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583 [TBL] [Abstract][Full Text] [Related]
27. Determination of bioequivalence of psychotropic drugs and concerns involving product interchange. Barone JA; Byerly WG J Clin Psychiatry; 1986 Sep; 47 Suppl():28-32. PubMed ID: 2875067 [TBL] [Abstract][Full Text] [Related]
28. Comparison of the bioequivalence of generic versus branded clozapine. Ereshefsky L; Glazer WM J Clin Psychiatry; 2001; 62 Suppl 5():25-7. PubMed ID: 11305845 [No Abstract] [Full Text] [Related]
29. Bioequivalence: the regulatory career of a pharmaceutical concept. Carpenter D; Tobbell DA Bull Hist Med; 2011; 85(1):93-131. PubMed ID: 21551918 [TBL] [Abstract][Full Text] [Related]
30. Tests for individual and population bioequivalence based on generalized p-values. McNally RJ; Iyer H; Mathew T Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750 [TBL] [Abstract][Full Text] [Related]
31. Aspects for bioavailability and bioequivalence revision: possible implications on clinical pharmacology. Ritschel WA Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):453-9. PubMed ID: 3683020 [No Abstract] [Full Text] [Related]
32. Levothyroxine dosage and the limitations of current bioequivalence standards. Hennessey JV Nat Clin Pract Endocrinol Metab; 2006 Sep; 2(9):474-5. PubMed ID: 16957756 [No Abstract] [Full Text] [Related]
33. United States Food and Drug Administration requirements for approval of generic drug products. Meyer MC J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846 [TBL] [Abstract][Full Text] [Related]
34. Some issues for the consideration of individual bioequivalence. Endrenyi L J Biopharm Stat; 1997 Mar; 7(1):35-9. PubMed ID: 9056586 [No Abstract] [Full Text] [Related]
35. Commentary on individual bioequivalence by M.-L. Chen. Hauck WW; Anderson S J Biopharm Stat; 1997 Mar; 7(1):13-6. PubMed ID: 9056582 [No Abstract] [Full Text] [Related]
36. [Bioequivalence of solid drug preparation]. Ejima A Eisei Shikenjo Hokoku; 1982; (100):1-20. PubMed ID: 6897833 [No Abstract] [Full Text] [Related]
37. Aspects of bioavailability and bioequivalence revision: possible implications on clinical pharmacology. Glasser AC Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):449-52. PubMed ID: 3683019 [No Abstract] [Full Text] [Related]
39. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Bialer M; Midha KK Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761 [TBL] [Abstract][Full Text] [Related]
40. A group sequential approach to crossover trials for average bioequivalence. Hauck WW; Preston PE; Bois FY J Biopharm Stat; 1997 Mar; 7(1):87-96. PubMed ID: 9056590 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]